Q&A

Is terazosin helpful in chronic prostatitis?

Author and Disclosure Information

  • BACKGROUND: Lifetime prevalence of chronic prostatitis in men aged 40 to 79 years is 5%, resulting in significant morbidity, unnecessary antibiotic use, and both patient and physician frustration.1 The vast majority of cases of chronic prostatitis are nonbacterial, recently termed chronic prostatitis/chronic pelvic pain syndrome by the National Institutes of Health (NIH) consensus classification of prostatitis syndromes.
  • POPULATION STUDIED: One hundred men aged 20 to 50 years were recruited from hospitals in Northern Malaysia (mostly of Chinese and Malay ethnicity) during a national prostatitis awareness campaign. Eligible men met NIH criteria for chronic prostatitis, with recent pain and decreased quality of life.
  • STUDY DESIGN AND VALIDITY: Subjects were randomly assigned in double-blind fashion to receive terazosin or identical placebo. It was not possible from the text to determine if allocation assignment was concealed. Terazosin was initiated at 1 mg/d and titrated as tolerated to 5 mg/d over 2 weeks, and continued for a total of 14 weeks. Outcomes were assessed at 2, 4, and 14 weeks using intention-to-treat analysis.
  • OUTCOMES MEASURED: The primary outcome measured was the quality-of-life item on the NIH-CPSI. Patients answered the questions 0 to 6 (0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible). Patients with scores of 0, 1, or 2 at week 14 were considered responders. The secondary outcome measured was a 50% or greater reduction in the NIH-CPSI pain domain score.
  • RESULTS: At week 14, 56% of patients receiving terazosin versus 33% receiving placebo responded to treatment (P=.03; number needed to treat [NNT]=4). More patients in the terazosin group reported a 50% decrease in pain domain scores (60% versus 37%; P=.03; NNT=4).


 

PRACTICE RECOMMENDATIONS

Terazosin, an alpha-1-adrenergic blocker, is well tolerated, relieves pain symptoms, and improves quality of life in healthy men aged 20 to 50 years who have chronic prostatitis/chronic pelvic pain syndrome.

Terazosin should be strongly considered as a first-line treatment in such patients. However, men with infectious prostatitis were excluded from this study. Also, the benefits of terazosin beyond 14 weeks are unknown.

Recommended Reading

Is prostate-specific antigen (PSA) screening indicated for any subgroup of men?
MDedge Family Medicine
What is the best diet to prevent recurrent calcium oxalate stones in patients with idiopathic hypercalciuria?
MDedge Family Medicine
Sexual Problems of Male Patients in Family Practice
MDedge Family Medicine
Does the manner in which information about prostate-specific antigen (PSA) testing is presented affect screening rates?
MDedge Family Medicine
Is tolterodine (Detrol) or oxybutynin (Ditropan) the best for treatment of urge urinary incontinence?
MDedge Family Medicine
Cigarette smoking and erectile dysfunction
MDedge Family Medicine
Infant circumcision
MDedge Family Medicine
Vasectomy not a risk factor for prostate cancer
MDedge Family Medicine
Korean red ginseng effective for treatment of erectile dysfunction
MDedge Family Medicine
Early radical prostatectomy improves disease-specific but not overall survival
MDedge Family Medicine